Perseo Pharma
Pre-clinicalWe are breaking new ground in the treatment of metabolic diseases Media Release Juni 3, 2024 Perseo pharma and Nestlé Health Science present the compelling preclinical data on PER301 for Exocrine Pancreatic Insufficiency at the DDW (Digestive Disease Week) conference in Washington on May 21, 2024.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $5M
About
We are breaking new ground in the treatment of metabolic diseases Media Release Juni 3, 2024 Perseo pharma and Nestlé Health Science present the compelling preclinical data on PER301 for Exocrine Pancreatic Insufficiency at the DDW (Digestive Disease Week) conference in Washington on May 21, 2024.
Drug Delivery
Funding History
1Total raised:$5M
Seed$5MMar 15, 2021